Actualités et Activités de Corvus Pharmaceuticals
Présence
Corvus Pharmaceuticals est une société cotée sous le symbole boursier CRVS (US).
Dirigeants
Voir l'organigramme avec ses 13 principaux dirigeants
Biographies les plus recherchées chez Corvus Pharmaceuticals
- Richard Miller, Chief Executive Officer and Chairman of the Board
- Scott Morrison, Director
- Linda Grais, Director
Changements de dirigeants chez Corvus Pharmaceuticals
- Richard Van Den Broek, a rejoint l'entreprise comme Director (publié le 10 avril 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez Corvus Pharmaceuticals.
Pharmacie
Corvus Pharmaceuticals a 1 833 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Eli Lilly (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Imbria Pharmaceuticals vient d'annoncer une levée de fonds de 58 millions de dollars. (publié le 10 avril 2025).
- Clario a acquis NRx Pharmaceuticals (publié le 18 mars 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publié le 12 mars 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Corvus Pharmaceuticals
- Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results | Corvus Pharmaceuticals
- Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma | Corvus Pharmaceuticals
- Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results | Corvus Pharmaceuticals
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Corvus Pharmaceuticals
- Corvus Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Corvus Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
